Details

Autor(en) / Beteiligte

• Samur, Mehmet Kemal
• Fulciniti, Mariateresa
• Aktas Samur, Anil
• Bazarbachi, Abdul Hamid
• Tai, Yu-Tzu
• Prabhala, Rao
• Alonso, Alejandro
• Sperling, Adam S.
• Campbell, Timothy
• Petrocca, Fabio
• Hege, Kristen
• Kaiser, Shari
• Loiseau, Hervé Avet
• Anderson, Kenneth C.
• Munshi, Nikhil C.

Titel

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Ist Teil von

• Nature communications, 2021-02, Vol.12 (1), p.868-868, Article 868

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment. We report selection, following initial CAR T cell infusion, of a clone with biallelic loss of BCMA acquired by deletion of one allele and a mutation that creates an early stop codon on the second allele. This loss leads to lack of CAR T cell proliferation following the second infusion and is reflected by lack of soluble BCMA in patient serum. Our analysis suggests the need for careful detection of BCMA gene alterations in multiple myeloma cells from relapse following CAR T cell therapy. Relapse following BCMA targeted CAR T-cell therapy is frequently observed in patients with multiple myeloma (MM). Here, by single cell transcriptome profiling on serially collected bone marrow samples, the authors report biallelic loss of BCMA as the mechanism of resistance underlying both relapse and lack of response to a second CAR T infusion in a patient with MM.